1. α7-Acetylcholine Receptor Signaling Reduces Neuroinflammation After Subarachnoid Hemorrhage in Mice
- Author
-
H. Alex Choi, Peeyush Kumar T, Spiros Blackburn, Kanako Matsumura, Jude P.J. Savarraj, Remya A Veettil, Ari Dienel, Jaroslaw Aronowski, Pramod K. Dash, and Devin W. McBride
- Subjects
0301 basic medicine ,Pharmacology ,Agonist ,Subarachnoid hemorrhage ,business.industry ,medicine.drug_class ,Inflammation ,medicine.disease ,Systemic inflammation ,03 medical and health sciences ,Nicotinic acetylcholine receptor ,030104 developmental biology ,0302 clinical medicine ,Nicotinic agonist ,medicine ,Galantamine ,Pharmacology (medical) ,Neurology (clinical) ,medicine.symptom ,business ,030217 neurology & neurosurgery ,Neuroinflammation ,medicine.drug - Abstract
Aneurysmal subarachnoid hemorrhage (aSAH) causes a robust inflammatory response which leads worse brain injury and poor outcomes. We investigated if stimulation of nicotinic acetylcholine α7 receptors (α7-AChR) (receptors shown to have anti-inflammatory effects) would reduce inflammation and improve outcomes. To investigate the level of peripheral inflammation after aSAH, inflammatory markers were measured in plasma samples collected in a cohort of aSAH patients. To study the effect of α7-AChR stimulation, SAH was induced in adult mice which were then treated with a α7-AChR agonist, galantamine, or vehicle. A battery of motor and cognitive tests were performed 24 h after subarachnoid hemorrhage. Mice were euthanized and tissue collected for analysis of markers of inflammation or activation of α7-AChR-mediated transduction cascades. A separate cohort of mice was allowed to survive for 28 days to assess long-term neurological deficits and histological outcome. Microglia cell culture subjected to hemoglobin toxicity was used to assess the effects of α7-AChR agonism. Analysis of eighty-two patient plasma samples confirmed enhanced systemic inflammation after aSAH. α7-AChR agonism reduced neuroinflammation at 24 h after SAH in male and female mice, which was associated with improved outcomes. This coincided with JAK2/STAT3 and IRAK-M activity modulations and a robust improvement in neurological/cognitive status that was effectively reversed by interfering with various components of these signaling pathways. Pharmacologic inhibition partially reversed the α7-AChR agonist’s benefits, supporting α7-AChR as a target of the agonist’s therapeutic effect. The cell culture experiment showed that α7-AChR agonism is directly beneficial to microglia. Our results demonstrate that activation of α7-AChR represents an attractive target for treatment of SAH. Our findings suggest that α7-AChR agonists, and specifically galantamine, might provide therapeutic benefit to aSAH patients.
- Published
- 2021
- Full Text
- View/download PDF